+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06239194

Phase 12a Study Evaluating MDX2001 Monotherapy for Advanced Solid Tumors A Multicenter, Open-label Clinical Trial Assessing Safety and Anti-tumor Activity

Led by ModeX Therapeutics, An OPKO Health Company · Updated on 2026-10-15

330

Participants Needed

6

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating MDX2001 for safety, tolerability, and anti-tumor activity in patients with advanced solid tumors. This study includes Phase 1a dose escalation, Phase 1b dose expansion in a single tumor type, and Phase 2a expansion. The goal is to identify a recommended dose for Phase 2 and assess how MDX2001 works in selected tumors. Participants receive MDX2001 either as an intravenous infusion or a subcutaneous injection. Treatment dosing and schedules vary across study phases, with patients in the expansion phases receiving the recommended Phase 2 dose. The studys duration per patient is expected to be around 10 months, including screening, treatment, and long-term follow-up. During the trial, participants undergo safety monitoring, tumor assessments, and evaluations of MDX2001s effects on their cancer. Researchers collect data on adverse events, tumor response, pharmacokinetics, immunogenicity, and tumor protein expression. Follow-up continues for several months after treatment to observe ongoing outcomes and safety.

CONDITIONS

Brief Title

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Research Team

E

Email recommended

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here